L'intérêt à découvert pour Bausch Health Companies donne aux investisseurs une idée du degré auquel les investisseurs parient sur la baisse de l'action de Bausch Health Companies. Les données sur l'intérêt à découvert sont mises à jour toutes les deux semaines.

Bausch Health Companies (NYSE:BHC) Stock, Rapport sur les intérêts à découvert

Bausch Health Companies

Bausch Health Companies Inc is a world-wide specialty pharmaceutical, consumer health, and medical device company with a focus on branded products for the gastroenterology, hepatology, neurology and dermatology markets. The company reports revenue in five segments: Salix; International; Solta Medical; Diversified Products and Bausch + Lomb. It generates maximum revenue from the Bausch + Lomb segment.

Bausch Health Cos

Bausch Health Companies Inc. Common Stock

Bausch Health Companies Inc

BillionHappiness

BENCHMARK HLDGS PLC by Benchmark Hldgs PLC

Benchmark Holdings PLC

AI-Driven Energy Pioneer Delivers Sixth Consecutive Record Month
Company on Clear Path to $100 Million Revenue Run-Rate with Canadian Acquisition
MIAMI, July 10, 2025 (GLOBE NEWSWIRE) -- NextNRG, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXXT#NASDAQ">NXXT</a>), a pioneer in AI-driven energy innovation transforming how energy is produced, managed, and delivered through its Next Utility Operating System&#xAE;, smart microgrids, wireless EV charging, and mobile fuel delivery, today announced preliminary unaudited financial results for June 2025.
June 2025 Highlights:
<ul>
<li>Revenue: $6.98 million, up 231% year-over-year and 6% month-over-month</li>
<li>Gallons delivered: Over 2.04 million gallons, up 270% year-over-year and 4% month-over-month</li>
<li>Year-to-date revenue through June reached approximately $35.87 million, representing a 33% increase over full-year 2024 revenue of approximately $27 million</li>
</ul>

News

NXXT

NextNRG Preliminary June 2025 Revenue Surges 231% Y/Y To $6.98M

Goldman Sachs analyst James Schneider initiates coverage on Qorvo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QRVO#NASDAQ">QRVO</a>) with a Neutral rating and announces Price Target of $90.

Price Target

Initiation

Analyst Ratings

QRVO

Goldman Sachs Initiates Coverage On Qorvo with Neutral Rating, Announces Price Target of $90

RBC Capital analyst Arun Viswanathan maintains Ameriprise Finl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMP#NYSE">AMP</a>) with a Outperform and raises the price target from $565 to $595.

RBC Capital Maintains Outperform on Ameriprise Finl, Raises Price Target to $595

<ul>
<li>Led by Dr. Mohit Bhandari, a pioneer in bariatric surgery and President of the Institute of Research Against Digestive Cancer (IRCAD) India, the surgery was remotely performed at a distance of 560 miles and executed on-site at Mohak Bariatric &amp; Robotic Surgery Centre in Indore, India.</li>
<li>Two advanced One-Anastomosis Gastric Bypass (OAGB) procedures were performed via telesurgery, with zero perceptible lag, flawless precision, and seamless robotic control using the SSI Mantra 3 system.</li>
</ul>
FORT LAUDERDALE, Fla., July 10, 2025 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=LXk68Zn9u8Lo5Lt1N2xDPtRZQaSJGsUeL6id-8x5QojmwvojHxhAKcJzUs9TlYGC378cOrWefJD61kcl8FJjKomGkvbTKXJm4o6u2pcS44ex-otaCjQ0fJG_D33XBJYC">SS Innovations International, Inc.</a> (the "Company" or "SS Innovations") (NASDAQ:<a href="https://www.benzinga.com/stock/SSII#NASDAQ">SSII</a>), a developer of innovative surgical robotic technologies dedicated to making robotic surgery affordable and accessible to a global population, today announced the successful completion of the world's first robotic telesurgery for weight loss utilizing the Company's advanced SSi Mantra 3 surgical robotic system.
This landmark bariatric telesurgery bridged a distance of 560 miles between SS Innovations' headquarters in Gurugram, India and the Mohak Bariatric &amp; Robotic Surgery Centre in Indore, India. Despite the vast distance, the surgery was performed with zero perceptible lag, flawless precision, and seamless robotic control, setting a new global benchmark for remote surgery capabilities.
The procedures involved two One-Anastomosis Gastric Bypass (OAGB) surgeries, an advanced form of bariatric surgery that reduces stomach size and reroutes the digestive tract to support long-term weight loss and improve metabolic health. The robotic procedures were successfully performed by Dr. Mohit Bhandari, a renowned bariatric surgeon, President of IRCAD India, and Founder &amp; Director of Mohak Bariatric &amp; Robotic Surgery Centre, Indore. Operating from Gurugram, Dr. Bhandari remotely led his Indore-based surgical team, which provided on-site assistance, ensuring expert execution and clinical excellence throughout.

Global

SSII

SS Innovations Completes World's First Robotic Telesurgery For Weight Loss Across 560 Miles In India

Goldman Sachs analyst James Schneider initiates coverage on ON Semiconductor (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ON#NASDAQ">ON</a>) with a Neutral rating and announces Price Target of $60.

Goldman Sachs Initiates Coverage On ON Semiconductor with Neutral Rating, Announces Price Target of $60

RBC Capital analyst Arun Viswanathan maintains Acadian Asset Management (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AAMI#NYSE">AAMI</a>) with a Sector Perform and raises the price target from $29 to $34.

AAMI

RBC Capital Maintains Sector Perform on Acadian Asset Management, Raises Price Target to $34

Delta Air Lines, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DAL#NYSE">DAL</a>) shares rose in premarket trading Thursday after the Atlanta-based carrier posted stronger-than-expected <a href="https://www.benzinga.com/pressreleases/25/07/n46338489/delta-air-lines-announces-june-quarter-2025-financial-results" target="_blank" rel="noreferrer noopener">second-quarter results</a> and reinstated its full-year 2025 guidance.
Operating revenue for the quarter was $16.65 billion, flat from a year ago but above the <a href="https://www.benzinga.com/earnings">consensus estimate</a> of $16.18 billion. Adjusted operating revenue rose 1% year over year to $15.51 billion.
Delta credited its June-quarter revenue, a 1% year-over-year increase, to continued strength in high-margin segments. Premium cabin sales rose 5%, loyalty revenue climbed 8%, American Express (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AXP#NYSE">AXP</a>) remuneration increased 10% to $2 billion, while adjusted unit revenue declined 3% amid 4% capacity growth.
Also Read: <a href="https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/07/46204250/airline-stocks-face-flat-q2-but-1-thing-could-lift-them" target="_blank" rel="noreferrer noopener">Airline Stocks Face Flat Q2—But 1 Thing Could Lift Them</a>
Adjusted earnings per share were $2.10, down 11% from the year-ago period but topping expectations of $2.05. The airline&#8217;s adjusted average fuel price fell to $2.26 per gallon, compared with $2.64 last year.
Passenger revenue surged 26% to $13.88 billion, while cargo revenue rose 7% to $212 million. Other revenue declined 2% to $2.57 billion.
Delta reported adjusted operating income of $2.05 billion, down from $2.27 billion a year earlier. Adjusted operating margin narrowed to 13.2% from 14.7%.
Adjusted operating cash flow totaled $1.84 billion, a 25% decline year over year, while free cash flow stood at $733 million.
As of the end of the June quarter, Delta reported adjusted net debt of $16.32 billion, down $1.7 billion from the end of 2024. Total liquidity was $6.4 billion, including $3.1 billion in undrawn revolver capacity.
The passenger load factor declined to 86% from 87% a year ago. Air traffic liability stood at $8.9 billion.
During the quarter, Delta announced new or expanded partnerships with WestJet, LATAM, IndiGo, and Virgin Atlantic, strengthening its global network and international connectivity.
&#8220;As we look to the second half of our centennial year, we remain focused on executing our strategic priorities and managing the levers within our control to deliver strong earnings and cash flow.&nbsp; Reflecting our confidence in the business, we are restoring financial&nbsp;guidance&nbsp;with an expectation for earnings per share of&nbsp;$5.25&nbsp;to&nbsp;$6.25&nbsp;and free cash flow of&nbsp;$3&nbsp;to&nbsp;$4 billion, consistent with our long-term free cash flow targets,&#8221; commented Ed Bastian, Delta&#8217;s chief executive officer.
Delta President Glen Hauenstein noted, &#8220;Through the quarter, demand trends stabilized at levels that are flat to last year and we continued to see resilience in our diverse, high-margin revenue streams.&#8221;
In June, DAL <a target="_blank" href="https://www.benzinga.com/pressreleases/25/06/n46013647/delta-air-lines-declares-quarterly-dividend" rel="noreferrer noopener">announced</a> a 25% increase to its quarterly dividend, raising it to $0.1875 per share. The payout is set for Aug. 21 to shareholders of record as of July 31.
<h2 class="wp-block-heading">2025 Outlook</h2>
Delta reinstated its full-year 2025 guidance, projecting earnings per share of $5.25 to $6.25, compared to the consensus estimate of $5.42. The airline also expects free cash flow of $3 billion to $4 billion.
&#8220;For the September quarter, we expect total revenue to be flat to up 4% compared to the prior year, with unit revenue trends expected to improve through the second half of the year as we continue to adjust capacity and the industry further rationalizes supply,&#8221; commented Glen Hauenstein, Delta&#8217;s president.
<h2 class="wp-block-heading">Third-Quarter 2025 Outlook</h2>
Delta forecasts total revenue to rise 0% to 4% year over year, with an operating margin between 9% and 11%. Adjusted earnings per share are projected to range from $1.25 to $1.75, versus a consensus estimate of $1.34.
Delta expects the September quarter to deliver its strongest non-fuel unit cost performance of the year, with costs projected to remain flat or decline slightly compared to 2024.
Price Action: DAL shares were trading higher by 12.03% to $56.76 premarket at last check Thursday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/politics/25/07/46336395/senate-confirms-trump-pick-bryan-bedford-as-faa-chief-even-as-chuck-schumer-warns-he-will-prioritize-profits-over-passenger-safety" target="_blank" rel="noreferrer noopener">Senate Confirms Trump Pick Bryan Bedford As FAA Chief Even As Chuck Schumer Warns He Will Prioritize &#8216;Profits Over Passenger Safety&#8217;</a></li>
</ul>
Photo by Angel DiBilio via Shutterstock

Earnings

Guidance

Movers

Delta Air Lines CEO Confident In Stronger 2025 As Demand Holds Steady

Goldman Sachs analyst James Schneider initiates coverage on Skyworks Solutions (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SWKS#NASDAQ">SWKS</a>) with a Sell rating and announces Price Target of $70.

SWKS

Goldman Sachs Initiates Coverage On Skyworks Solutions with Sell Rating, Announces Price Target of $70

Goldman Sachs analyst James Schneider initiates coverage on Analog Devices (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADI#NASDAQ">ADI</a>) with a Buy rating and announces Price Target of $285.

Goldman Sachs Initiates Coverage On Analog Devices with Buy Rating, Announces Price Target of $285

Goldman Sachs analyst James Schneider initiates coverage on Microchip Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCHP#NASDAQ">MCHP</a>) with a Buy rating and announces Price Target of $88.

MCHP

Goldman Sachs Initiates Coverage On Microchip Technology with Buy Rating, Announces Price Target of $88

RBC Capital analyst Arun Viswanathan maintains FMC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FMC#NYSE">FMC</a>) with a Sector Perform and raises the price target from $40 to $47.

RBC Capital Maintains Sector Perform on FMC, Raises Price Target to $47

RBC Capital analyst Arun Viswanathan maintains Corteva (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CTVA#NYSE">CTVA</a>) with a Outperform and raises the price target from $74 to $85.

CTVA

RBC Capital Maintains Outperform on Corteva, Raises Price Target to $85

Goldman Sachs analyst James Schneider initiates coverage on Texas Instruments (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TXN#NASDAQ">TXN</a>) with a Buy rating and announces Price Target of $225.

Goldman Sachs Initiates Coverage On Texas Instruments with Buy Rating, Announces Price Target of $225

<a href="https://d1io3yog0oux5.cloudfront.net/_cc809716af22826d6b497dbdf8d85863/omegahealthcare/db/2905/27976/pdf/Omega+Healthcare+-+New+Investor+Presentation+-+July+10+2025+v1.pdf" title="https://d1io3yog0oux5.cloudfront.net/_cc809716af22826d6b497dbdf8d85863/omegahealthcare/db/2905/27976/pdf/Omega+Healthcare+-+New+Investor+Presentation+-+July+10+2025+v1.pdf">https://d1io3yog0oux5.cloudfront.net/_cc809716af22826d6b497dbdf8d85863/omegahealthcare/db/2905/27976/pdf/Omega+Healthcare+-+New+Investor+Presentation+-+July+10+2025+v1.pdf</a>

Omega Healthcare Investors Issues 2025 July Investor Presentation

WIIM

K Wave Media shares are trading higher after the company announced it has secured a $1 billion capacity to drive its Bitcoin treasury strategy. Additionally, the company has raised $500 million through a convertible note agreement.

Goldman Sachs analyst James Schneider initiates coverage on Marvell Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRVL#NASDAQ">MRVL</a>) with a Neutral rating and announces Price Target of $75.

MRVL

Goldman Sachs Initiates Coverage On Marvell Tech with Neutral Rating, Announces Price Target of $75

DeFi Development Corp. (NASDAQ:<a href="https://www.benzinga.com/stock/DFDV#NASDAQ">DFDV</a>) (the "Company") the first public company with a treasury strategy built to accumulate and compound Solana ("SOL"), announced today the purchase of 153,225 Solana ("SOL") at an average purchase price of $154.85 and valued at approximately $23.72 million. Following this transaction, DeFi Dev Corp. now holds approximately 846,630 SOL and SOL equivalents, including staking rewards, making the Company the largest Solana treasury company, by both total holdings and market capitalization.
The latest purchase was funded, in part, by $9.65 million in net proceeds from the exercise of the greenshoe option tied to the Company's previously announced convertible note offering. Below is a summary of DeFi Dev Corp.'s current SOL position and key per-share metrics as of July 10, 2025:
<ul>
<li>Total SOL &amp; SOL Equivalents Held: 846,630</li>
<li>Total SOL &amp; SOL Equivalents Held (USD): approximately $133.1 million</li>
<li>Total Shares Outstanding: 18,577,134</li>
<li>SOL per Share ("SPS"): 0.0456</li>
<li>SPS (USD): $7.16</li>
</ul>
Shares outstanding are as of July 9, 2025. The most recently purchased SOL will be held long-term and staked to a variety of validators, including DeFi Dev Corp.'s own Solana validators to generate native yield.
The Company will continue to provide suitable updates to our Treasury and underlying strategies, through public releases and regulatory filing(s), as available. &nbsp;

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Markets

DFDV

DeFi Dev Corp. Buys 153,225 SOL For ~$23.72M, Bringing Total Holdings To 846,630 SOL

Goldman Sachs analyst James Schneider initiates coverage on ARM Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARM#NASDAQ">ARM</a>) with a Neutral rating and announces Price Target of $160.

Goldman Sachs Initiates Coverage On ARM Holdings with Neutral Rating, Announces Price Target of $160

The Cato Institute and the New Civil Liberties Alliance (NCLA) have called on the Federal Circuit to strike down President Donald Trump&#8216;s tariffs, arguing they rely on a statute that does not grant any authority to impose such tariffs.
What Happened:&nbsp;According to briefs filed by the Cato Institute and the NCLA, the International Emergency Economic Powers&nbsp;Act (IEEPA) does not give the president authority to impose tariffs, Reason <a href="https://reason.com/2025/07/09/appeals-court-briefs-say-trumps-tariffs-are-based-on-a-statute-that-does-not-authorize-tariffs-at-all/">reported</a>. They argue that the Constitution grants that power exclusively to Congress.
The CIT's decision in VOS Selections v. Trump concluded that neither set of tariffs—intended to curb drug trafficking and reduce trade deficits—was authorized under the IEEPA. The Trump administration is now challenging the ruling through an appeal.
In two briefs filed on Tuesday, the Cato Institute and NCLA contend that the CIT should have taken a broader stance by declaring that the IEEPA does not authorize tariffs &#8220;at all.&#8221;
The CIT ruling addressed two categories of tariffs: duties on imports from China, Mexico, and Canada, and the &#8220;Liberation Day&#8221; tariffs affecting goods from nearly all nations. In both instances, Trump cited an &#8220;unusual and extraordinary threat&#8221; and declared a &#8220;national emergency&#8221; under the IEEA to justify the measures.
Both Cato and the NCLA maintain that the statute does not grant the president &#8220;an unbounded tariff authority.&#8221; In their Federal Circuit briefs, they argue that the IEAA provides no tariff authority to the president at all. &#8220;The Constitution vests the power to impose tariffs solely in Congress,&#8221; the Cato brief asserts.
They argue that the IEEPA was meant to &#8220;limit,&#8221; not expand, executive power, citing legal doctrines that limit presidential authority without clear congressional approval.
SEE ALSO:&nbsp;<a href="https://benzinga.com/markets/tech/25/07/46334695/mark-zuckerberg-once-revealed-that-getting-into-harvard-made-his-mom-and-dad-prouder-than-building-f" target="_blank" rel="noreferrer noopener">Mark Zuckerberg Once Revealed That Getting Into Harvard Made His Mom And Dad Prouder Than Building Facebook —Spills The Beans On Why No One Talked To Him At His First Class</a>
Why It Matters: This development comes after a federal appeals court&nbsp;allowed Trump&#8217;s tariffs to <a href="https://www.benzinga.com/news/legal/25/06/45877448/appeals-court-allows-trumps-tariffs-to-remain-in-effect-while-it-reviews-the-lower-courts-decision">remain in effect</a>&nbsp;while reviewing the lower court decisions that blocked the duties on constitutional grounds. The&nbsp;U.S. Court of Appeals for&nbsp;the Federal Circuit granted a temporary stay, preserving Trump&#8217;s &#8220;Liberation Day&#8221; tariffs on most trading partners and separate duties on Canada, China, and Mexico.
Meanwhile, Treasury Secretary Scott Bessent has&nbsp;cautioned that countries failing to <a href="https://www.benzinga.com/markets/macro-economic-events/25/07/46269036/scott-bessent-says-tariff-rates-set-to-boomerang-back-in-august-for-countries-failing-to-strike-a-deal">negotiate a deal </a>with the U.S. will face a return to higher tariff rates&nbsp;from August 1. The 90-day pause on the &#8220;reciprocal&#8221; tariffs, initially declared on April 2 and paused for 90 days a week later, is scheduled to conclude on July 9. Bessent clarified that the new effective date does not represent a new deadline or an extension of the original timeline.
On the other hand, billionaire investor Ray Dalio&nbsp;warned that Trump&#8217;s latest <a href="https://www.benzinga.com/markets/macro-economic-events/25/07/46338641/ray-dalio-says-trumps-tariffs-are-theoretical-warns-they-may-not-bring-manufacturing-back-to-us">round of tariffs</a> could deepen &#8220;stagflation&#8221; and may never deliver on promises to revive U.S. factory floors.
<ul class="wp-block-list">
<li>READ MORE: <a href="https://www.benzinga.com/markets/economic-data/25/07/46288472/japans-prime-minister-criticizes-trumps-tariff-decision-shigeru-ishiba-calls-move-truly-regrettable">Japan&#8217;s Prime Minister Criticizes Trump&#8217;s Tariff Decision: Shigeru Ishiba Calls Move &#8216;Truly Regrettable&#8217; </a></li>
</ul>
Image via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Cato Institute, NCLA Urge Appeals Court To Reject Trump Tariffs Citing Unauthorized Use Of Statute: Report

Advanced Micro Devices shares are trading higher after HSBC upgraded the stock from Hold to Buy and announced a price target of $200.

Legal

Press Releases

U.S. District Court Grants Summary Judgment in Favor of FDA, Salix, and Teva, and Against Norwich

Bausch Health Announces Filing of Supplement to Proxy Statement

Bausch Health Announces Launch of Solta Medical's Fraxel FTX(TM)

Bausch Health Announces Health Canada Clearance of Solta Medical's Thermage(R) FLX System

Bausch Health Announces First Quarter 2025 Results

Xifaxan(R) (rifaximin) Treatment Following Overt Hepatic Encephalopathy (OHE) Hospitalization Associated with Reduced Risk of 30-Day OHE Rehospitalization

Bausch Health Announces 2025 Annual Meeting of Shareholder Results

Bausch Health to Announce Second Quarter 2025 Results on July 30

Bausch Health's Gastroenterology Business, Salix Pharmaceuticals, Launches Fresh "I Wish I Knew" Campaign to Educate People About Xifaxan(R) (rifaximin) for Adults at Risk of Overt Hepatic Encephalopathy Recurrence

Bausch Health, Canada Inc. Treatment for Acne Vulgaris, (Pr)CABTREO(TM) (clindamycin phosphate, adapalene and benzoyl peroxide gel), Now Available Through Public Drug Plans of Ontario, Quebec and Two Federal Programs

Comments

Bausch Health Companies

Intérêt court

Bausch Health Companies (NYSE:BHC) Stock, Rapport sur les intérêts à découvert

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL